Humana Reaches New 52-Week High

Zacks

On Jul 11, 2013, the shares of Humana Inc. (HUM) reached a new 52-week high of $86.50. The momentum was driven by the company’s fundamental strength, including higher earnings and Medicare coverage, strong financials, sturdy ratings and an efficient inorganic growth strategy.

Humana has maintained a strong cash and short-term investment position over the past several years. The strong cash position enabled the company to increase its quarterly dividend by 3.85% in Apr 2013, after a 4% dividend hike in Apr 2012.

Moreover, Humana’s individual Medicare stand-alone prescription drugs plan membership has been increasing over the past few years, driven by strategic alliances and competitive pricing. It grew 17.5% in 2012 and 8.9% in the first quarter of 2013. For 2013, the company expects it to increase by 170,000–190,000.

This membership increase should boost Humana’s revenues from the Medicare business, which contributed 72% of the total premiums and service revenues in 2012. The company’s strong earnings and membership growth in the first quarter prompted management to increase the earnings guidance for 2013 to $8.40–$8.60 per share from $7.60–$7.80.

Humana expects its second-quarter earnings in the range of $2.40–$2.50 per share. The Zacks Consensus Estimate for Humana’s second-quarter 2013 earnings stands at $2.46, which is within the company’s guidance range. This translates into a year-over-year increase of 5.03%.

Moreover, the valuation of Humana looks attractive. The shares are trading at a discount to its peers both on a price-to-book and on a forward price-to-earnings basis, while the return on equity of 15.9% is higher than the peer group average of 12.5%. The year-to-date return from the stock is 25.6%, above S&P’s return of 17.4%.

Humana currently carries a Zacks Rank #3 (Hold). Other health maintenance organizations worth considering are Molina Healthcare Inc. (MOH) – Zacks Rank #1 (Strong Buy), Aetna Inc. (AET) – Zacks Rank #2 (Buy) and WellPoint Inc. (WLP) – Zacks Rank #2 (Buy).

Read the Full Research Report on WLP

Read the Full Research Report on AET

Read the Full Research Report on HUM

Read the Full Research Report on MOH

Zacks Investment Research



More From Zacks.com

Rates

View Comments (0)